SCHEMBL7394693

SCHEMBL7394693

Oc1ccc(-c2nc3cc(Cl)ccc3[nH]2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
ALDH1A1 P00352 4/20 0.54
HPGD P15428 4/20 0.54
MEN1 O00255 3/20 0.54
TP53 P04637 3/20 0.54
KMT2A Q03164 3/20 0.54
HSD17B10 Q99714 3/20 0.54
MAPT P10636 2/20 0.54
CYP3A4 P08684 1/20 0.54
MAPK1 P28482 1/20 0.54
FTO Q9C0B1 1/20 0.54
NPC1 O15118 3/20 0.51
RAB9A P51151 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
APP P05067 1/20 0.51
GAA P10253 1/20 0.51
NFKB1 P19838 1/20 0.51
SNCA P37840 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9032997 0.92 ALDH1A1 (0.62) KDM4EALDH1A1HPGDMEN1TP53
SCHEMBL3335014 0.90 ALDH1A1 (0.61) KDM4EALDH1A1HPGDMEN1TP53
SCHEMBL7394696 0.87 MEN1 (0.71) KDM4EALDH1A1HPGDMEN1TP53
SCHEMBL5579984 0.86 CHEK1 (0.59) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL415254 0.86 CHEK1 (0.55) ALDH1A1HPGDMEN1KMT2AHSD17B10
SCHEMBL15245092 0.84 KDM4E (0.71) KDM4EALDH1A1HPGDMEN1TP53
SCHEMBL5761334 0.84 ALDH1A1 (0.68) KDM4EALDH1A1HPGDMEN1TP53
SCHEMBL10380499 0.84 ALDH1A1 (0.54) KDM4EALDH1A1HPGDMEN1TP53
SCHEMBL22955330 0.84 KDM4E (0.71) KDM4EALDH1A1HPGDMEN1TP53
SCHEMBL3333026 0.84 KDM4E (0.61) KDM4EALDH1A1HPGDMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626893-A1 NOVEL PHTHALOCYANINE COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF DISEASES Rhodes University (ZA) 2025-10-08 EP disclosed
WO-2024115968-A1 NOVEL PHTHALOCYANINE COMPOUNDS AND THE USE THEREOF FOR THE TREATMENT OF DISEASES RHODES UNIVERSITY (ZA) 2024-06-06 WO disclosed
US-7705031-B2 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-27 US disclosed
US-7705031-B2 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-04-27 US disclosed
US-20080306129-A1 BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2008-12-11 US disclosed
US-20080306129-A1 BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2008-12-11 US disclosed
US-7309716-B2 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-18 US disclosed
US-7309716-B2 Benzimidazoles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-18 US disclosed
WO-2001066526-A1 ESTER DERIVATIVES OF DIMETHYLPROPIONIC ACID AND PHARMACETUICAL COMPOSITIONS CONTAINING THEM CERMOL S.A. (CH) 2001-09-13 WO disclosed
EP-1132381-A1 Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them CERMOL S.A. (CH) 2001-09-12 EP disclosed
US-4714762-A Antiarteriosclerotic substituted benzimidazol-2-yl-and 3H-imidazo[4,5-b]pyridin-2-yl-phenoxy-alkanoic acids and salts and esters thereof WARNER-LAMBERT COMPANY (US) 1987-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306129-A1 BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS KCNJ11, KCNJ1, KCNJ2 KDM4E 1468/4885ALDH1A1 484/4885HPGD 2950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.